The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic.
about
Treatment Options for Carbapenem-Resistant Enterobacteriaceae InfectionsParenteral colistin for the treatment of severe infections: a single center experience.Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii.Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections.Clinical outcomes associated with polymyxin B dose in patients with bloodstream infections due to carbapenem-resistant Gram-negative rodsOptimizing Polymyxin Combinations Against Resistant Gram-Negative BacteriaPharmacokinetics and renal disposition of polymyxin B in an animal model.Multicenter Prospective Cohort Study of Renal Failure in Patients Treated with Colistin versus Polymyxin B.Evaluation of Risk Factors for Intravenous Colistin Use-related NephrotoxicityPolymyxin B Induces Apoptosis in Kidney Proximal Tubular Cells.Risk factors for treatment failure of polymyxin B monotherapy for carbapenem-resistant Klebsiella pneumoniae infectionsPolymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use.In vitro assessment and multicenter cohort study of comparative nephrotoxicity rates associated with colistimethate versus polymyxin B therapy.Adverse reactions associated with systemic polymyxin therapy.To B or not to B, that is the question: is it time to replace colistin with polymyxin B?The safety of polymyxin antibiotics.Polymyxin B versus colistin: an update.Development of new polymyxin derivatives for multi-drug resistant Gram-negative infections.Dosing and Pharmacokinetics of Polymyxin B in Patients with Renal Insufficiency.Resurgence of Polymyxin B for MDR/XDR Gram-Negative Infections: An Overview of Current Evidence.Risk factors for nephrotoxicity onset associated with polymyxin B therapy.Risk factors for acute kidney injury (AKI) in patients treated with polymyxin B and influence of AKI on mortality: a multicentre prospective cohort study.Comparison of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia and tracheobronchitis caused by Pseudomonas aeruginosa or Acinetobacter baumannii.Dose adjustment of polymyxins for renal insufficiency.A multicenter case-case control study for risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii bacteremia.Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside.Population Pharmacokinetics of Polymyxin B.Methionine Ameliorates Polymyxin-Induced Nephrotoxicity by Attenuating Cellular Oxidative Stress.Severe Infusion-Related Adverse Events and Renal Failure in Patients Receiving High-Dose Intravenous Polymyxin B.Personalizing Polymyxin B Dosing Using an Adaptive Feedback Control Algorithm.
P2860
Q28082546-06BAF43F-FA74-4932-95F6-9AD0BBEA5428Q33653353-E94576E5-15BE-4A50-AB2D-819578ED3535Q35385769-01C07011-1717-43FD-BFB5-3316DDE42B59Q36076006-3F400D1C-E9B3-4899-9326-8351BA35C442Q36158501-EF2213E4-DC2A-402C-9F52-F3814ABFB82CQ36363261-18C186F5-2332-4060-A384-327B92AEBF91Q36364194-1B7BF593-62C3-4AF4-839F-5C38B8255519Q36730174-2EC81006-2CCD-4303-B5DD-42C781C0864AQ37053617-0389F30B-CEFD-439B-8D13-ADEDF68BE317Q37124019-D94E1BD7-CC38-4C26-A7F1-C21D5498ECFBQ37263364-EA0C90F9-E8AA-46CA-8D31-E94E5960BCBCQ37562099-010D7C06-F635-416F-AA8E-1784421E8967Q37712983-8AA9FDBC-7B77-47BC-B67F-35ADBE1FA336Q38255373-BE2FDEA8-3872-4649-95F6-220A0207AFBEQ38262873-F1936470-C65F-4274-BAC0-803294FE3CD9Q38586123-E385D5AC-EDEF-4064-94FF-B425D0D2E9ECQ38613051-C23224A2-FCAB-4AB6-82A9-7675446B8F9CQ39078589-0FFE2D09-A93C-4E48-839A-14C9F3DD46A1Q40035349-171CCD87-6E91-4370-A510-18EADFA5A986Q40111993-71EB4DC4-D41A-4309-8EF4-F7F4AECC393FQ41477519-CEE5FBFE-43A1-4D03-B77D-7294D70D91EDQ41532045-807902AC-899D-4A4A-8582-80638C31AAFEQ42287771-323D74F7-67BF-4BFC-A4D9-E5AB9CDB9A3EQ42931272-76442A86-0BE0-4F5F-8720-C19A60D769CAQ43574348-A89C80D9-DF6E-4519-94CA-B7953A3AF2D2Q43607805-29981E5A-06B2-4BB9-9A2A-FE884A5BDE2CQ47313113-3D4626DE-BD21-4A90-BAB1-E0231F7BBBAEQ47735607-87845430-15CB-4889-BEA7-1BF3F1D47864Q47781226-D6BFB447-B361-4EF4-B085-0035461F56FCQ53682528-05208734-7910-4074-A435-5E2452DB6AA1
P2860
The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
The impact of polymyxin B dosa ...... treated with this antibiotic.
@en
The impact of polymyxin B dosa ...... treated with this antibiotic.
@nl
type
label
The impact of polymyxin B dosa ...... treated with this antibiotic.
@en
The impact of polymyxin B dosa ...... treated with this antibiotic.
@nl
prefLabel
The impact of polymyxin B dosa ...... treated with this antibiotic.
@en
The impact of polymyxin B dosa ...... treated with this antibiotic.
@nl
P2093
P2860
P356
P1476
The impact of polymyxin B dosa ...... treated with this antibiotic.
@en
P2093
Alexandre P Zavascki
Daniele Konzen
Juliana M Krebs
Laura S Elias
P2860
P304
P356
10.1093/JAC/DKQ285
P407
P577
2010-08-04T00:00:00Z